Stem Cell-Derived Dendritic Platforms for Standardized CD4+ T Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for isolating and characterizing antigen-specific CD4+ T cell populations are limited by the variability in preparing primary dendritic cells and the heterogeneity of HLA-DR receptors, making it difficult to develop universal probes for autoimmune disorders.
Innovation Solution
The use of human embryonic stem cell-derived dendritic cells, which are customizable to present any peptide antigen, allowing for standardized analysis of CD4+ T cell responses and expansion of antigen-specific T cell populations for therapeutic purposes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If primary dendritic cells are used for antigen presentation, then T cell expansion can be achieved, but variability in cell preparation and HLA-DR heterogeneity reduce reliability and standardization
Solution Approach 1:
The patent uses engineered antigen-presenting cells that copy the essential function of primary dendritic cells while eliminating their variability. These engineered cells express standardized HLA-DR molecules and can be produced in a controlled manner, providing a reliable template that reproduces consistent antigen presentation across different preparations and patients.
Solution Approach 2:
The invention changes the key parameters of antigen-presenting cells by engineering them to express standardized HLA-DR molecules with specific characteristics. This involves modifying cell lines to maintain constant HLA-DR expression levels and properties, thereby transforming the variable primary cells into standardized reagents with controlled parameters for reliable T cell expansion.
2Adaptability or versatility
If customized antigen presentation is implemented, then versatility in diagnosing different autoimmune disorders is improved, but system complexity increases
Solution Approach 1:
The patent creates a universal engineered antigen-presenting cell platform that can serve multiple functions across different autoimmune disorders. The engineered cells are designed with standardized components that can present various antigens by simply changing the peptide input, making the system versatile for diagnosing different conditions without requiring separate complex systems for each disorder.
Solution Approach 2:
The invention segments the antigen presentation system into modular components: standardized engineered antigen-presenting cells that provide consistent HLA-DR expression, separate peptide antigen inputs that can be customized for different disorders, and controlled culture conditions. This segmentation allows flexibility in antigen selection while maintaining system simplicity through standardized cell components.
Data Source
AI summary
The invention relates to methods, peptides, nucleic acids and cells for use in isolating and expanding human T cell populations in an antigen-specific manner for immunodiagnostic or therapeutic purposes. The invention also relates to professional antigen presenting cells derived from pluripotent human stem cells, and to customizable antigen presentation by the antigen presenting cells.